Mitochondrial DNA 4977 bp Deletion in Peripheral Blood Is Associated With Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is a common endocrine disorder worldwide. We aimed to examine the associations of two mitochondrial DNA (mtDNA) biomarkers in the peripheral blood, mtDNA copy number (CN), and mtDNA deletion rate (DR), with PCOS in a clinical setting. We performed a study involving 2...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2021-07, Vol.12, p.675581-675581
Main Authors: Ye, Mujin, Hu, Bin, Shi, Weihui, Guo, Fei, Xu, Chenming, Li, Shuyuan
Format: Article
Language:English
Subjects:
Adult
Biomarkers - blood
Body Mass Index
Case-Control Studies
China - epidemiology
DNA Copy Number Variations
DNA, Mitochondrial - genetics
Endocrinology
Female
Follow-Up Studies
Humans
infertility
mitochondria
Mitochondria - genetics
mitochondrial DNA copy number
mitochondrial DNA deletion
polycystic ovary syndrome
Polycystic Ovary Syndrome - blood
Polycystic Ovary Syndrome - epidemiology
Polycystic Ovary Syndrome - genetics
Polycystic Ovary Syndrome - pathology
Prognosis
Sequence Deletion
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polycystic ovary syndrome (PCOS) is a common endocrine disorder worldwide. We aimed to examine the associations of two mitochondrial DNA (mtDNA) biomarkers in the peripheral blood, mtDNA copy number (CN), and mtDNA deletion rate (DR), with PCOS in a clinical setting. We performed a study involving 263 women with PCOS and 326 age-matched controls between June 2015 and June 2019. The mtDNA CN and mtDNA DR were measured using multiplex probe-based qPCR. The associations of the mtDNA CN and mtDNA DR with the risk of PCOS were estimated using logistic regression. Analysis of the associations between mtDNA biomarkers and PCOS indicate that the mtDNA CN ( = 0.003) and mtDNA DR ( < 0.001) in PCOS patients were significantly higher than those in the controls. After adjusting for the body mass index, luteinizing hormone/follicle-stimulating hormone ratio, and testosterone level, only higher mtDNA DR was associated with PCOS (odds ratio 1.053, 95% confidence interval 1.024 to 1.083; < 0.001). The linear dose-response trends of the mtDNA DR were also supported by the quartile analysis. Multivariable models suggest that mtDNA DR levels are strongly associated with PCOS and represent an independent risk factor for PCOS. Further investigation of the utility of mtDNA as a biomarker for PCOS is warranted.
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2021.675581